Vaccine research has increasingly focused on virus-like particles (VLPs) due to their unique ability to mimic the structures of viruses without containing ...
In the Virus-Like Particle Translational Oncology Laboratory, Qizhi Cathy Yao, M.D., Ph.D. is developing non-infectious HIV virus-like particles (VLPs) as candidate HIV mucosal vaccines for both ...
The following is a summary of "Impact of HBsAg reduction via siRNA treatment on natural and vaccine (BRII-179)-induced ...
ProBioGen has expanded its protein and viral vector manufacturing capabilities at its Berlin headquarters, reinforcing its ...
The formation of VLP is depicted in Figure 1. Figure 1. The formation of a virus-like particle (VLP). Image Credit: Sino Biological Inc. To enable targeted drug research, Sino Biological has ...
GlobalData on MSN10d
EC approves Bavarian Nordic’s chikungunya vaccine marketingThe EC has authorised the marketing of Bavarian Nordic's Vimkunya chikungunya vaccine for individuals as young as 12 years ...
COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the European Commission has granted marketing authorization in Europe for VIMKUNYA ® for active ...
The virus particle comes apart ... viruses are then released from the cell and can go on to infect other cells. Like other viruses, the dengue virus is a microscopic structure that can only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback